Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy

被引：47
作者：
Figueroa-Espada, Christian G. [1 ]
Hofbauer, Samuel [1 ]
Mitchell, Michael J. [1 ,3 ,4 ,5 ,6 ]
Riley, Rachel S. [1 ,2 ]
机构：
[1] Univ Penn, Dept Bioengn, 210 South 33rd St, Philadelphia, PA 19104 USA
[2] Rowan Univ, Dept Biomed Engn, 201 Mullica Hill Rd, Glassboro, NJ 08028 USA
[3] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Univ Penn, Inst Immunol, Perelman Sch Med, Philadelphia, PA 19104 USA
[5] Univ Penn, Cardiovasc Inst, Perelman Sch Med, Philadelphia, PA 19104 USA
[6] Univ Penn, Inst Regenerat Med, Perelman Sch Med, Philadelphia, PA 19104 USA
来源：
ADVANCED DRUG DELIVERY REVIEWS | 2020年 / 160卷
基金：
美国国家卫生研究院; 美国国家科学基金会;
关键词：
Placenta; Drug delivery technologies; Nanoparticle; Pregnancy; Active targeting; Pre-eclampsia; IN-VITRO; GOLD NANOPARTICLES; CATIONIC LIPIDS; P-GLYCOPROTEIN; GENE-TRANSFER; QUANTUM DOTS; PLASMID DNA; TRANSPORT; MODEL; MICE;
D O I：
10.1016/j.addr.2020.09.006
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
A major challenge to treating diseases during pregnancy is that small molecule therapeutics are transported through the placenta and incur toxicities to the developing fetus. The placenta is responsible for providing nutrients, removing waste, and protecting the fetus from toxic substances. Thus, the placenta acts as a biological barrier between the mother and fetus that can be exploited for drug delivery. Nanoparticle technologies provide the opportunity for safe drug delivery during pregnancy by controlling how therapeutics interact with the placenta. In this Review, we present nanoparticle drug delivery technologies specifically designed to exploit the placenta as a biological barrier to treat maternal, placental, or fetal diseases exclusively, while minimizing off-target toxicities. Further, we discuss opportunities, challenges, and future directions for implementing drug delivery technologies during pregnancy. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页码：244 / 261
页数：18
相关论文
共 151 条
[11]  
[Anonymous], 2019, INT J MOL SCI
[12]  
[Anonymous], 2019, C ELECT INSUL DIEL P
[13]   Distribution and accumulation of 10 nm silver nanoparticles in maternal tissues and visceral yolk sac of pregnant mice, and a potential effect on embryo growth [J].
Austin, Carlye A. ;
Hinkley, Georgia K. ;
Mishra, Anurag R. ;
Zhang, Qin ;
Umbreit, Thomas H. ;
Betz, Martha W. ;
Wildt, Bridget E. ;
Casey, Brendan J. ;
Francke-Carroll, Sabine ;
Hussain, Saber M. ;
Roberts, Stephen M. ;
Brown, Ken M. ;
Goering, Peter L. .
NANOTOXICOLOGY, 2016, 10 (06) :654-661
[14]  
Barzago MM, 1996, J PHARMACOL EXP THER, V277, P79
[15]   Placental Homing Peptide-microRNA Inhibitor Conjugates for Targeted Enhancement of Intrinsic Placental Growth Signaling [J].
Beards, Frances ;
Jones, Lisa E. ;
Charnock, Jayne ;
Forbes, Karen ;
Harris, Lynda K. .
THERANOSTICS, 2017, 7 (11) :2940-2955
[16]   Pharmacokinetic considerations in the use of anticancer drugs during pregnancy: challenges and new developments [J].
Bell, David J. ;
Kerr, David J. .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (09) :1341-1344
[17]   Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology [J].
Bertrand, Nicolas ;
Wu, Jun ;
Xu, Xiaoyang ;
Kamaly, Nazila ;
Farokhzad, Omid C. .
ADVANCED DRUG DELIVERY REVIEWS, 2014, 66 :2-25
[18]   Circulating exosomal and Argonaute-bound microRNAs in preeclampsia [J].
Biro, Orsolya ;
Fothi, Abel ;
Alasztics, Balint ;
Nagy, Balint ;
Orban, Tamas I. ;
Rigo, Janos, Jr. .
GENE, 2019, 692 :138-144
[19]   A microphysiological model of the human placental barrier [J].
Blundell, Cassidy ;
Tess, Emily R. ;
Schanzer, Ariana S. R. ;
Coutifaris, Christos ;
Su, Emily J. ;
Parry, Samuel ;
Huh, Dongeun .
LAB ON A CHIP, 2016, 16 (16) :3065-3073
[20]   Liposomal Formulations in Clinical Use: An Updated Review [J].
Bulbake, Upendra ;
Doppalapudi, Sindhu ;
Kommineni, Nagavendra ;
Khan, Wahid .
PHARMACEUTICS, 2017, 9 (02)
12345678910